Carprofen

CHEMBL1316 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
273.7 g/mol
LogP
4.0
Phase
4

A nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes, reducing the production of prostaglandins responsible for pain and inflammation. While it was once used in humans, it is now primarily employed in veterinary medicine for pain relief in dogs. Gastrointestinal and renal adverse effects are associated with its use.

分子量

273.7100 g/mol

LogP

4.00

TPSA

53.10 Ų

リピンスキーの五則

適合

治療領域

作用機序

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C(=O)O)c1ccc2c(c1)[nH]c1ccc(Cl)cc12

InChI

InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)

Molecular Formula

C15H12ClNO2

HBD / HBA

2 / 2

回転可能結合数

2

重原子数

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes, reducing the production of prostaglandins responsible for pain and inflammation. While it was once used in humans, it is now primarily employed in veterinary medicine for pain relief in dogs. Gastrointestinal and renal adverse effects are associated with its use.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Carprofen is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1316. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2581. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.